Skip to main
ALT
ALT logo

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune Inc. demonstrates a positive outlook due to pemvidutide's significant clinical results, including weight loss of up to 6.2% at 24 weeks and substantial liver fat reduction of up to 62.8%, alongside notable improvements in histological endpoints and biomarker measures. The evidence of anti-fibrotic activity, as indicated by reductions in ELF and VCTE scores, supports the drug's potential effectiveness in treating metabolic-associated steatohepatitis (MASH). Additionally, the strengthening of Altimmune's leadership team positions the company well for key upcoming catalysts, further enhancing confidence in pemvidutide's advancement to Phase 3 trials.

Bears say

Altimmune Inc. is currently experiencing a significant decline in its stock value, with shares down approximately 55%, despite its promising clinical prospects for its product candidate, pemvidutide, aimed at treating obesity and metabolic-associated steatohepatitis. The company faces multiple risks that contribute to a negative outlook, including clinical development, commercialization, competitor challenges, reimbursement uncertainties, and potential capital market dilution. Additionally, external factors such as potential COVID-19 disruptions and geopolitical tensions from the ongoing war in Eastern Europe further exacerbate the uncertainties surrounding Altimmune's financial stability and future prospects.

Altimmune (ALT) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Altimmune (ALT) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.